147 related articles for article (PubMed ID: 27686442)
1. [The efficacy analysis of interferon combined with imatinib in chronic myelogenous leukemia patients with ABL kinase domain mutations].
Zu YL; Zhang YL; Zhou J; Zhao HF; Gui RR; Li Z; Gao SK; Song YP
Zhonghua Nei Ke Za Zhi; 2016 Oct; 55(10):794-796. PubMed ID: 27686442
[TBL] [Abstract][Full Text] [Related]
2. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
3. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.
Kim SH; Kim D; Kim DW; Goh HG; Jang SE; Lee J; Kim WS; Kweon IY; Park SH
Hematol Oncol; 2009 Dec; 27(4):190-7. PubMed ID: 19274615
[TBL] [Abstract][Full Text] [Related]
5. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients.
Qin Y; Chen S; Jiang B; Jiang Q; Jiang H; Li J; Li L; Lai Y; Liu Y; Huang X
Ann Hematol; 2011 Jan; 90(1):47-52. PubMed ID: 20697894
[TBL] [Abstract][Full Text] [Related]
7. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).
Nicolini FE; Corm S; Lê QH; Sorel N; Hayette S; Bories D; Leguay T; Roy L; Giraudier S; Tulliez M; Facon T; Mahon FX; Cayuela JM; Rousselot P; Michallet M; Preudhomme C; Guilhot F; Roche-Lestienne C
Leukemia; 2006 Jun; 20(6):1061-6. PubMed ID: 16642048
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
9. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India.
Kagita S; Uppalapati S; Jiwatani S; Linga VG; Gundeti S; Nagesh N; Digumarti R
Tumour Biol; 2014 Jul; 35(7):7187-93. PubMed ID: 24763825
[TBL] [Abstract][Full Text] [Related]
11. Mutations in ABL kinase domain are associated with inferior progression-free survival.
Sharma P; Mohanty S; Kochupillai V; Kumar L
Leuk Lymphoma; 2010 Jun; 51(6):1072-8. PubMed ID: 20367437
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
Sherbenou DW; Hantschel O; Kaupe I; Willis S; Bumm T; Turaga LP; Lange T; Dao KH; Press RD; Druker BJ; Superti-Furga G; Deininger MW
Blood; 2010 Oct; 116(17):3278-85. PubMed ID: 20519627
[TBL] [Abstract][Full Text] [Related]
13. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Shah NP; Nicoll JM; Nagar B; Gorre ME; Paquette RL; Kuriyan J; Sawyers CL
Cancer Cell; 2002 Aug; 2(2):117-25. PubMed ID: 12204532
[TBL] [Abstract][Full Text] [Related]
14. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
15. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
Al-Ali HK; Heinrich MC; Lange T; Krahl R; Mueller M; Müller C; Niederwieser D; Druker BJ; Deininger MW
Hematol J; 2004; 5(1):55-60. PubMed ID: 14745431
[TBL] [Abstract][Full Text] [Related]
16. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
Donato NJ; Wu JY; Stapley J; Lin H; Arlinghaus R; Aggarwal BB; Shishodia S; Albitar M; Hayes K; Kantarjian H; Talpaz M
Cancer Res; 2004 Jan; 64(2):672-7. PubMed ID: 14744784
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?
Gruber FX; Lundán T; Goll R; Silye A; Mikkola I; Rekvig OP; Knuutila S; Remes K; Gedde-Dahl T; Porkka K; Hjorth-Hansen H
Med Oncol; 2012 Mar; 29(1):219-26. PubMed ID: 21221851
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.
Nicolini FE; Hayette S; Corm S; Bachy E; Bories D; Tulliez M; Guilhot F; Legros L; Maloisel F; Kiladjian JJ; Mahon FX; Lê QH; Michallet M; Roche-Lestienne C; Preudhomme C
Haematologica; 2007 Sep; 92(9):1238-41. PubMed ID: 17768119
[TBL] [Abstract][Full Text] [Related]
20. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Branford S; Rudzki Z; Walsh S; Parkinson I; Grigg A; Szer J; Taylor K; Herrmann R; Seymour JF; Arthur C; Joske D; Lynch K; Hughes T
Blood; 2003 Jul; 102(1):276-83. PubMed ID: 12623848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
